Beta Drugs Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
as on 12-08-2024
- Paid Up Capital ₹ 9.61 Cr
as on 12-08-2024
- Company Age 19 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 31.24 Cr
as on 12-08-2024
- Satisfied Charges ₹ 18.89 Cr
as on 12-08-2024
- Revenue 26.42%
(FY 2023)
- Profit 32.08%
(FY 2023)
- Ebitda 24.06%
(FY 2023)
- Net Worth 24.26%
(FY 2023)
- Total Assets 20.87%
(FY 2023)
About Beta Drugs
It is listed on the National Stock Exchange(NSE) under the ticker symbol BETA.
The Corporate was formerly known as Beta Drugs Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 9.61 Cr.
The company currently has active open charges totaling ₹31.24 Cr. The company has closed loans amounting to ₹18.89 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Beta Drugs Limited India are Nipun Arora as CFO and Rajni Charaya as Company Secretary. Balwant Singh, Varun Batra, Rahul Batra, and Four other members serve as directors at the Company.
- CIN/LLPIN
L24230HP2005PLC028969
- Company No.
028969
- Stock Symbol
NSE : BETA
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
21 Sep 2005
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Listed
- ROC Code
Roc Himachal Pradesh
Industry
Company Details
- Location
Solan, Himachal Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Beta Drugs?
Executive Team (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Varun Batra  | Managing Director | 01-Aug-2014 | Current |
| Rahul Batra | Managing Director | 01-Aug-2014 | Current |
| Nipun Arora | CFO | 05-Mar-2021 | Current |
| Rajni Charaya | Company Secretary | 17-Jul-2017 | Current |
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Manmohan Khanna | Director | 26-Jul-2017 | Current |
| Balwant Singh | Whole-Time Director | 01-Aug-2014 | Current |
| Rohit Parti | Director | 26-Jul-2017 | Current |
| Seema Chopra | Whole-Time Director | 01-Aug-2019 | Current |
| Ashutosh Shukla | Whole-Time Director | 20-Jan-2022 | Current |
Financial Performance of Beta Drugs.
Beta Drugs Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 26.42% increase. The company also saw a substantial improvement in profitability, with a 32.08% increase in profit. The company's net worth Soared by an impressive increase of 24.26%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Beta Drugs?
In 2022, Beta Drugs had a promoter holding of 66.71% and a public holding of 33.29%. The company had 2 Subsidiaries. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Adley Formulations Private LimitedActive 6 years 2 monthsVarun Batra, Rahul Batra and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 29 Jul 2024 | ₹1.66 M | Open |
Uco Bank Creation Date: 02 Apr 2024 | ₹7.50 Cr | Open |
Others Creation Date: 27 Feb 2024 | ₹1.70 M | Open |
How Many Employees Work at Beta Drugs?
Beta Drugs has a workforce of 309 employees as of Aug 12, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Beta Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Beta Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
